Understanding the consequences of chronic inflammatory demyelinating polyradiculoneuropathy from impairments to activity and participation restrictions and reduced quality of life: the ICE study
| Autor: | Merkies, Is, Hughes, Ra, Donofrio, P, Bril, V, Dalakas, Mc, Hanna, K, Hartung, Hp, Latov, N, van Doorn, Pa, Deng, C, Ice, Sg, Adamova, B, Apostolski, S, Banach, M, Barroso, F, Bartosik Psujek, H, Basta, I, Belniak, E, Buchman, A, Caress, J, Chyrchel, U, Cho, S, Comi, G, Dacci, P, Drory, V, Dubrovsky, A, Fazio, R, Fryze, W, Fulgenzi, E, Gonzalez Cornejo, S, Gonzalez Jaime, Jd, Grandis, Marina, Haas, J, Kaminski, M, Kwiecinski, H, Marchesoni, C, Munch, C, Nations, S, Pardal, Am, Patwa, H, Pavlovic, S, Reisin, R, Romero Vargas, S, Ruiz Sandoval, Jl, Ruiz Sandoval, Md, Stelmasiak, Z, Szczudlik, A, Thomas, Fp, Tsao, B, Uncini, A, Villa, A, Vohanka, S, Wolfe, G, Zapletalova, O, Zielinska, M. |
|---|---|
| Přispěvatelé: | Klinische Neurowetenschappen, RS: MHeNs School for Mental Health and Neuroscience, Neurology |
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Male
medicine.medical_specialty Neural Conduction CIDP Placebo law.invention Disability Evaluation Grip strength Double-Blind Method Randomized controlled trial Quality of life law intravenous immunoglobulin randomized trial Humans Medicine Initial treatment Baseline (configuration management) Retrospective Studies impairments Hand Strength business.industry General Neuroscience Immunoglobulins Intravenous Polyradiculoneuropathy Retrospective cohort study medicine.disease humanities Treatment Outcome Polyradiculoneuropathy Chronic Inflammatory Demyelinating disability quality of life Physical therapy Regression Analysis Female Neurology (clinical) business Follow-Up Studies |
| Zdroj: | Journal of the Peripheral Nervous System, 15(3), 208-215. Wiley Journal of the Peripheral Nervous System, 15(3), 208-215. Wiley-Blackwell Publishing Ltd |
| ISSN: | 1529-8027 1085-9489 |
| Popis: | A randomized trial (ICE trial) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) demonstrated significantly more improvement with intravenous immunoglobulin (Gamunex(®), Talecris Biotherapeutics, Inc., Research Triangle Park, NC) than placebo. To understand the relationship between CIDP impairments, activity and participation restrictions, and quality of life (QoL) in this trial, we investigated the association between scales representing these outcome levels. Gamunex or placebo was given every 3 weeks for up to 24 weeks to 117 patients in an initial treatment period after which treatment failures were crossed over (alternative treatment). We assessed impairments, activity and participation, and SF-36 component mental (MCS) and physical summaries (PCS). Regression analyses of baseline data were performed (all subjects) and change from baseline to endpoint (Gamunex-treated group only) to determine correlations between outcomes. Grip strength, medical research council (MRC) sum score, and inflammatory neuropathy cause and treatment (INCAT) sensory sum score were the strongest explanatory variables of disability (at baseline: r(2) = 0.46; change from baseline: r(2) = 0.66). Only up to half of the variance in QoL scores (PCS at baseline: r(2) = 0.30; change from baseline: r(2) = 0.41; MCS: at baseline: r(2) = 0.10; change from baseline: r(2) = 0.24) was explained by impairment and activity and participation measures. Future studies are required to elucidate the impact of CIDP on disability and QoL changes, because the obtained correlations provide only partial explanation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|